Recessive dystrophic epidermolysis bullosa
MONDO:0009179Severe generalized recessive dystrophic epidermolysis bullosa (RDEB-sev gen) is the most severe subtype of dystrophic epidermolysis bullosa (DEB), formerly known as the Hallopeau-Siemens type, and is characterized by generalized cutaneous and mucosal blistering and scarring associated with severe deformities and major extracutaneous involvement.
Also known as: EBD inversa, RDEB generalisata gravis, RDEB, Hallopeau-Siemens type, RDEB-sev gen, autosomal recessive dystrophic epidermolysis bullosa generalisata gravis, autosomal recessive dystrophic epidermolysis bullosa, Hallopeau-Siemens type, epidermolysis bullosa dystrophica, AR, epidermolysis bullosa dystrophica, autosomal recessive, modifier of
24 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New hope for blistering skin diseases: drug targets antibodies to heal wounds
Disease control Not yet recruitingThis early-phase study tests whether the drug efgartigimod (VYVGART) can lower harmful collagen VII antibodies and improve wound healing in people with two rare blistering skin conditions: recessive dystrophic epidermolysis bullosa (RDEB) and epidermolysis bullosa acquisita (EBA)…
Phase: PHASE1, PHASE2 • Sponsor: M. Peter Marinkovich • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New cream could help kids with 'Butterfly Skin' heal faster
Disease control Not yet recruitingThis phase 3 trial tests whether a cream called SD-101 can help close wounds in children with epidermolysis bullosa (EB), a condition that causes fragile, blistering skin. About 80 children aged 1 month to 12 years will apply the cream or a placebo to their whole body for 2 month…
Phase: PHASE3 • Sponsor: Paradigm Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New cream aims to soothe butterfly skin in Late-Stage trial
Symptom relief Not yet recruitingThis Phase 3 study tests the safety of SD-101 cream (6% allantoin) in 80 people with epidermolysis bullosa, a condition that causes fragile, blistering skin. Participants must have completed a prior study (SD-007). The main goal is to track any side effects over time.
Phase: PHASE3 • Sponsor: Paradigm Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC
-
Skin deep: european study probes the hidden emotional toll of skin diseases
Knowledge-focused Not yet recruitingThis study looks at how people with skin conditions (like eczema, psoriasis, or skin cancer) manage stress, feel lonely, and bounce back from challenges. Researchers will compare 375 adults with and without skin disease across 15 European countries using questionnaires. The goal …
Phase: NA • Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC